Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells

Lung Cancer

Volumn 75, Issue 1, 2012, Pages 95-101

  Tao, Hiroyuki ^a   Mimura, Yusuke ^a   Aoe, Keisuke ^a   Kobayashi, Seiki ^a   Yamamoto, Hiromasa ^a   Matsuda, Eisuke ^a   Okabe, Kazunori ^a   Matsumoto, Tsuneo ^a   Sugi, Kazurou ^a   Ueoka, Hiroshi ^a  

^a NATIONAL SANYO HOSPITAL   (Japan)

Author keywords

FOXP3; Non small cell lung cancer (NSCLC); Prognostic factor; Regulatory T cell (Treg)

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER CELL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; T-LYMPHOCYTES, REGULATORY;

EID: 83555174415     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.06.002     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Pisters K.M., Evans W.K., Azzoli C.G., Kris M.G., Smith C.A., Desch C.E., et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007, 25:5506-5518.
3. Potti A., Ganti A.K. Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future. Expert Opin Biol Ther 2006, 6:709-716.
4. Johansson M., Denardo D.G., Coussens L.M. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154.
5. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
6. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
7. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12:5423-5434.
8. Kobayashi N., Hiraoka N., Yamagami W., Ojima H., Kanai Y., Kosuge T., et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007, 13:902-911.
9. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24:5373-5380.
10. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009, 69:2000-2009.
11. Jordanova E.S., Gorter A., Ayachi O., Prins F., Durrant L.G., Kenter G.G., et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?. Clin Cancer Res 2008, 14:2028-2035.
12. Mizukami Y., Kono K., Kawaguchi Y., Akaike H., Kamimura K., Sugai H., et al. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008, 98:148-153.
13. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593.
14. Petersen R.P., Campa M.J., Sperlazza J., Conlon D., Joshi M.B., Harpole D.H., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
15. Shimizu K., Nakata M., Hirami Y., Yukawa T., Maeda A., Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010, 5:585-590.
16. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
17. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
18. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
19. Hinz S., Pagerols-Raluy L., Oberg H.H., Ammerpohl O., Grussel S., Sipos B., et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007, 67:8344-8350.
20. Ebert L.M., Tan B.S., Browning J., Svobodova S., Russell S.E., Kirkpatrick N., et al. The regulatory T cell-associated transcription factor Foxp3 is expressed by tumor cells. Cancer Res 2008, 68:3001-3009.
21. Merlo A., Casalini P., Carcangiu M.L., Malventano C., Triulzi T., Menard S., et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009, 27:1746-1752.
22. Ladoire S., Arnould L., Mignot G., Coudert B., Rebe C., Chalmin F., et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011, 125:65-72.
23. Zuo T., Liu R., Zhang H., Chang X., Liu Y., Wang L., et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007, 117:3765-3773.
24. Wang L., Liu R., Li W., Chen C., Katoh H., Chen G.Y., et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009, 16:336-346.
25. Perrone G., Ruffini P.A., Catalano V., Spino C., Santini D., Muretto P., et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008, 44:1875-1882.
26. Roos-Engstrand E., Ekstrand-Hammarstrom B., Pourazar J., Behndig A.F., Bucht A., Blomberg A. Influence of smoking cessation on airway T lymphocyte subsets in COPD. COPD 2009, 6:112-120.
27. Barcelo B., Pons J., Ferrer J.M., Sauleda J., Fuster A., Agusti A.G. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+regulatory T-lymphocyte response to tobacco smoking. Eur Respir J 2008, 31:555-562.
28. Granville C.A., Memmott R.M., Balogh A., Mariotti J., Kawabata S., Han W., et al. A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS One 2009, 4:e5061.
29. Martin F., Ladoire S., Mignot G., Apetoh L., Ghiringhelli F. Human FOXP3 and cancer. Oncogene 2010, 29:4121-4129.
30. Jung D.J., Jin D.H., Hong S.W., Kim J.E., Shin J.S., Kim D., et al. Foxp3 expression in p53-dependent DNA damage responses. J Biol Chem 2010, 285:7995-8002.
31. Zheng S.G., Wang J., Horwitz D.A. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008, 180:7112-7116.
32. Enewold L., Mechanic L.E., Bowman E.D., Zheng Y.L., Yu Z., Trivers G., et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009, 18:215-222.
33. Zhou Z., Song X., Li B., Greene M.I. FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol Res 2008, 42:19-28.